Syneron Medical Ltd. Transitions UltraShape® Business to Direct Sales in Canada
YOKNEAM, Israel, Aug. 1, 2012 /PRNewswire/ -- Syneron Medical Ltd. (NASDAQ: ELOS), the global leader in medical aesthetic products and technology, announced today the complete transition of its UltraShape® business in Canada from its previous distribution network to the Company's Canadian headquarters in Toronto, Canada which includes, but is not limited to, sales, service and customer support. This news comes shortly following the Company's acquisition of UltraShape Ltd. on February 8, 2012.
"The swift progress to Syneron's Canadian headquarters in Toronto represents our continued commitment to this region, its existing UltraShape customers, and is a positive step towards driving increased adoption of UltraShape in Canada," said Louis P. Scafuri, Chief Executive Officer of Syneron. "We are very excited to bring all entities of the UltraShape business in Canada closer to our strong existing infrastructure providing new and existing UltraShape customers with direct access to the world-class business and service support that have earned Syneron its leading position in the worldwide medical aesthetic market."
The UltraShape Contour |V3 system, the latest model by UltraShape, is cleared and commercially available in Canada as well as in Europe, Canada, Latin America and Asia. For more information about UltraShape visit www.syneron.com.
UltraShape's proprietary technology emits patented pulsed focused ultrasound energy that prompt an instant mechanical (non-thermal) destruction of fat cells selectively and permanently destroying unwanted fat cells in problematic areas such as the abdomen, flanks and thighs without affecting critical surrounding structures. The UltraShape Contour |V3 system, the latest model by UltraShape, is approved and commercially available within Syneron's worldwide network in Canada, Europe, Latin America and Asia.
About Syneron Medical Ltd.
Syneron Medical Ltd. (NASDAQ: ELOS) is the leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, rejuvenation of the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under two distinct brands, Syneron and Candela. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&D and manufacturing operations in the US. The Company markets, services and supports its products in 90 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide.
SOURCE Syneron Medical Ltd.